Hyperoside blocks the AKT pathway, which reduces the protein expression of B-type natriuretic peptide and β-myosin heavy chain by angiotensin II (Ang II) or enhances SIRT3 signal expression to improve cardiac hypertrophy [55,59]. The gene discussed is AGT; the disease is cardiac hypertrophy.